HeSAPP is a single-center, non-blinded, parallel-group randomized controlled trial studying the hemopurification strategy for acute paraquat(PQ) poisoned patients. The intervention to be investigated include hemodialysis (HD), hemoperfusion (HP), combined hemoperfusion-hemodialysis consecutive therapy (HP-HD) and conservative therapy. The hypothesis of this study is that patients receiving hemopurification therapy would have a lower rate of mortality, and HP-HD would be superior to the other three therapies in mortality reduction.